Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Covid link to inflammation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 18, 2021 2:04pm
169 Views
Post# 32321158

RE:Covid link to inflammation

RE:Covid link to inflammation
Jjjj12345 wrote: Seems like a long term side effect of covid is inflammation of joints. https://abc7.com/covid-long-haulers-symptoms/9632046/

While that sucks it seems like it could be even a larger market share for something like ATE.


JJJJ12345 ... you may have helped me answer some of my own questions.

Looking at your article, he COVID related study may very well be more related to the Aspirin side of business.  If that were true, it would explain many of the discrepencies with the last two shareholder updates (and what was mentioned at BioPUB).

The fact that we're not running Aspirin in parallel to ATB-340 at this time is  the give-a-way.

-----

intead ...
since collaboration on the Aspirin side (COVID),
the company decided to run the IBD drugs with a new molecule (unexpected).
OTENA is going to P3.
352 is making its way to human studies and fast-track.

In this manner, all our candidates are progressing forward.  How lucky would that be ?

Exciting - if true.   Hmmmmmmm


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities